Cleveland Clinic
VC Fund
Cleveland, United States
Cleveland Clinic is a non-profit academic medical center that integrates clinical and hospital care with research and education. Its mission is to provide better care for the sick, investigate their problems, and further the education of those who serve.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $7.5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Cleveland Clinic invests in
Stages Cleveland Clinic invests in
Countries Cleveland Clinic invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Akhil Saklecha
|
|||
Dennis L. Laraway
|
|||
Joseph Nally
|
|||
Pamela Miller
|
|||
Samuel Miller
|
|||
| See all 15 contacts → | |||
Investment Focus
Industry
- Health Care 13 (50%)
- Medical 6 (23%)
- Therapeutics 5 (19%)
- Biotechnology 4 (15%)
- Medical Device 4 (15%)
Stage
- Series A 9 (35%)
- Series B 5 (19%)
- Funding Round 3 (12%)
- Seed 2 (8%)
- Series C 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Akhil Saklecha
Managing Director
|
Managing Director | Total investments: 3 | Find email | |
|
Dennis L. Laraway
Chief Financial Officer
|
Chief Financial Officer | Total investments: 1 | Find email | |
|
Joseph Nally
Nephrologist
|
Nephrologist | Total investments: 0 | Find email | |
|
Pamela Miller
Chairman of the Board of Directors
|
Chairman of the Board of Directors | Total investments: 0 | Find email | |
|
Samuel Miller
Member of the Board of Directors
|
Member of the Board of Directors | Total investments: 0 | Find email | |
| See all 15 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Enspire DBS Therapy
|
Enspire DBS Therapy supports stroke recovery patients using deep brain stimulation with physical rehabilitation to restore motor function. Enspire DBS offers a robust method to mediate the effects of stimulation and stroke rehabilitation. | $10.3M / Series B / Jan 13, 2026 | |
Mediview XR
|
MediView AR, LLC is a startup Ohio based medical device company that has designed and patented intellectual property in development of Extended Reality Surgical Navigation with intended use in ablation and biopsy of cancerous tumors. | $24M / Series A / Oct 06, 2025 | |
Method AI
|
Method AI is developing an AI-backed surgical navigation platform to drive improved patient outcomes for robotic surgical oncology procedures. | $20M / Series A / Aug 21, 2025 | |
Method AI
|
Method AI is developing an AI-backed surgical navigation platform to drive improved patient outcomes for robotic surgical oncology procedures. The company’s product will leverage deep tissue imaging and machine learning algorithms to provide physicians with real-time guidance against a best outcome surgical plan. | $20M / Series A / Aug 21, 2025 | |
1m
|
1m is a healthtech company that offers a software platform for risk management and performance improvement services. | $7.3M / Series A / Dec 12, 2024 | |
|
1m
|
1m is a healthtech company that offers a software platform for risk management and performance improvement services. | $7.3M / Series A / Dec 12, 2024 | |
XII Medical
|
XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea. | $45M / Series B / Aug 21, 2024 | |
|
Strolll
|
Strolll Neurotechnology | $3M / Corporate Round / Aug 20, 2024 | |
Neuro Therapia
|
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M / Series B / Aug 06, 2024 | |
|
Neuro Therapia
|
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M / Series B / Aug 06, 2024 | |
| See all 26 investments → | |||
Co-Investors
JobsOhio
9 deals together
Banner Health
4 deals together
GE Healthcare
4 deals together
Alzheimer's Drug Discovery Foundation
3 deals together
Brain Trust Accelerator Fund
3 deals together
Dolby Family Ventures
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cleveland Clinic invest in?
Cleveland Clinic invests primarily in Health Care, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cleveland Clinic?
Public channels for Cleveland Clinic include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cleveland Clinic?
The team at Cleveland Clinic includes Akhil Saklecha (Managing Director), Dennis L. Laraway (Chief Financial Officer) and Joseph Nally (Nephrologist), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
